Denali Therapeutics Inc.
Denali Therapeutics Inc.（DNLI）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · DNLI · 截至 2026年6月9日
活动摘要
买入笔数
2
P-Purchase only
卖出笔数
6
近12个月
买卖比
0.33
Buy/Sell (by trades)
整体情绪
Denali Therapeutics Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
DNLI 季度内部人买卖趋势
DNLI 内幕交易卖出 · DNLI 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · DNLI CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
DNLI 高管卖出股份 · DNLI 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 3, 2026 | FLATLEY JAY T Director | Award | 6,408 | — | Form 4 |
| Jun 3, 2026 | Klein Peter S Director | Award | 6,408 | — | Form 4 |
| Jun 3, 2026 | Krognes Steve E. Director | Award | 6,408 | — | Form 4 |
| Jun 3, 2026 | Schenkein David P Director | Award | 6,408 | — | Form 4 |
| Jun 3, 2026 | Thornberry Nancy Director | Award | 6,408 | — | Form 4 |
| Jun 3, 2026 | Van Hauwermeiren Timothy Director | Award | 6,408 | — | Form 4 |
| Jun 3, 2026 | Cook Jennifer E. Director | Award | 6,408 | — | Form 4 |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP Director | Award | 6,408 | — | Form 4 |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP Director | Award | 6,408 | — | Form 4 |
| Jan 6, 2026 | Watts Ryan J. President and CEO · Director | Sale | 35,198 | $581K | Form 4 |
| Jan 6, 2026 | Schuth Alexander O. COFO and Secretary | Sale | 17,218 | $284K | Form 4 |
| Jan 3, 2026 | Schuth Alexander O. COFO and Secretary | Award | 57,700 | — | Form 4 |
| Jan 3, 2026 | Watts Ryan J. President and CEO · Director | Award | 78,960 | — | Form 4 |
| Nov 4, 2025 | Van Hauwermeiren Timothy Director | Award | 10,632 | — | Form 4 |
| Sep 3, 2025 | Watts Ryan J. President and CEO · Director | Gift | 50,000 | — | Form 4 |
| Aug 12, 2025 | Schuth Alexander O. COFO and Secretary | Sale | 2,937 | $40K | Form 4 |
| Aug 12, 2025 | Ho Carole Chief Medical Officer | Sale | 2,937 | $40K | Form 4 |
| Aug 13, 2025 | Ho Carole Chief Medical Officer | Sale | 806 | $12K | Form 4 |
| Aug 5, 2025 | Ho Carole Chief Medical Officer | Option | 44,655 | $30K | Form 4 |
| Jul 9, 2025 | Watts Ryan J. President and CEO · Director | Option | 40,000 | $211K | Form 4 |
| Jul 9, 2025 | Watts Ryan J. President and CEO · Director | Option | 455,282 | $310K | Form 4 |
| Jul 9, 2025 | Watts Ryan J. President and CEO · Director | Sale | 495,282 | $7.43M⚡ | Form 4 |
| Jun 3, 2025 | BAKER BROS. ADVISORS LP Director | Award | 10,565 | — | Form 4 |
| Jun 3, 2025 | BAKER BROS. ADVISORS LP Director | Award | 10,565 | — | Form 4 |
| Jun 3, 2025 | Cook Jennifer E. Director | Award | 6,037 | — | Form 4 |
Watts Ryan J.
President and CEO · Director
日期
Jul 9
股数
455,282
均价
$0.68
总金额
$310K
Watts Ryan J.
President and CEO · Director
日期
Jul 9
股数
495,282
均价
$15.00
总金额
$7.43M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 DNLI 内幕交易
DNLI 内幕交易
Denali Therapeutics Inc.（DNLI）内幕交易数据来源于公司内部人（包括Watts Ryan J. (President and CEO · Director), Schuth Alexander O. (COFO and Secretary), Ho Carole (Chief Medical Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。DNLI内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Denali Therapeutics Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
DNLI 内幕交易 · 5个问题Denali Therapeutics Inc.（DNLI）的内部人包括高管和董事，如Watts Ryan J. (President and CEO · Director), Schuth Alexander O. (COFO and Secretary), Ho Carole (Chief Medical Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026